RXR a potential minimal residual disease target in melanoma

New research into the biology of solid tumor minimal residual disease (MRD) has revealed retinoid X receptor (RXR) as a potential target to delay development of drug resistance

Read the full 289 word article

How to gain access

Continue reading with a
two-week free trial.